Comprehensive Study Notes: Myasthenia Gravis vs. Glaucoma
Overview of Autonomic Nervous System Dysfunctions
System Function: The autonomic nervous system regulates involuntary physiological processes throughout the body.
Mechanisms of Failure: Pathologies of the autonomic nervous system manifest through distinct underlying physiological mechanisms rather than a uniform pathway:
Receptor-Level Communication Failure: Characterized by profound neurotransmitter imbalances and autoimmune-mediated receptor destruction (exemplified by Myasthenia Gravis).
Structural Fluid Dynamics Failure: Driven by dysregulation of fluid pathways and pathologically elevated physical pressure (exemplified by Glaucoma).
Myasthenia Gravis: Pathophysiology and Cascade
Disease Definition: A chronic autoimmune neuromuscular junction disorder characterized by progressive, fatiguable skeletal muscle weakness.
Pathophysiologic Mechanism:
The immune system produces autoantibodies that target, block, and destroy nicotinic acetylcholine receptors at the postsynaptic neuromuscular junction.
Despite motor nerves firing and releasing acetylcholine, muscle fibers fail to receive adequate chemical signals due to the physical destruction of functional receptors.
Step-by-Step Pathophysiologic Cascade:
Autoimmune Attack: Production of circulating autoantibodies targeting postsynaptic acetylcholine receptors.
Receptor Depletion: Severe quantitative reduction and loss of available acetylcholine receptors.
Impaired Transmission: When a nerve impulse arrives, an insufficient quantity of acetylcholine binds to receptors, leading to an incomplete muscle contraction.
Clinical Manifestation: Progressive muscle fatigability wherein repeated muscle use directly increases weakness.
Primary Open-Angle Glaucoma: Pathophysiology and Fluid Dynamics
Disease Definition: A progressive optic neuropathy characterized by structural damage to the optic nerve head, leading to predictable visual field loss.
Pathophysiologic Mechanism:
Glaucoma is driven by increased physical resistance within the eye's aqueous humor drainage apparatus.
Inability to clear aqueous fluid leads to fluid buildup, elevated intraocular pressure, and mechanical compression/ischemia of the optic nerve.
Aqueous Humor Outflow Pathways:
Primary Pathway (Trabecular Meshwork): Clears of total aqueous humor from the eye. Clogging or physical resistance within this pathway is the primary root cause of primary open-angle glaucoma.
Secondary Pathway (Uveoscleral Outflow Pathway): Clears the remaining of aqueous humor outflow.
Triggers and Clinical Presentations
Myasthenia Gravis Presentation:
Physical Symptoms: Visible, fatiguable weakness including drooping eyelids (ptosis), double vision (diplopia), and difficulty swallowing (dysphagia).
Systemic Stress Triggers: Everyday stressors can trigger exacerbations, including active infections, surgical procedures, pregnancy, or extreme stress.
Exacerbating Pharmacologic Agents:
Beta-blockers.
Antibiotics (specifically fluoroquinolones and aminoglycosides).
Magnesium sulfate.
Medical Emergency (Myasthenic Crisis): Severe exacerbation causing profound weakness of the respiratory muscles, resulting in an inability to breathe without mechanical ventilation.
Primary Open-Angle Glaucoma (POAG) Presentation:
Physical Symptoms: Silent and insidious onset.
Visual Field Loss: Causes gradual, painless loss of peripheral vision without ocular redness, often remaining undetected by the patient until late stages.
Primary Angle-Closure Glaucoma (PACG) Presentation:
Physical Symptoms: Acute, sudden-onset attack featuring severe eye pain, perception of halos around light sources, and a fixed mid-dilated pupil.
Anatomic Triggers: Any event inducing pupillary dilation (mydriasis), causing the iris to bunch up and occlude the iridocorneal drainage angle.
Demographic and Structural Risk Factors: Advanced age, female sex, and farsightedness (hyperopia).
Exacerbating Pharmacologic Agents:
Anticholinergics.
Adrenergic agonists (e.g., pseudoephedrine found in over-the-counter cold remedies).
Tricyclic antidepressants.
Medical Emergency: Acute angle closure causes immediate intraocular pressure spikes that can lead to rapid, permanent vision loss without immediate intervention.
Diagnostic Workups and Modalities
Myasthenia Gravis Diagnostic Tools:
Edrophonium (Tensilon) Test: Intravenous administration of edrophonium (a short-acting acetylcholinesterase inhibitor) temporarily halts acetylcholine degradation, causing muscle weakness to temporarily reverse.
Serologic Testing: Assays detecting circulating anti-acetylcholine receptor (anti-ACHR) antibodies, which test positive in approximately of cases.
Electrophysiological Testing: Repetitive nerve stimulation and single-fiber electromyography (SFEMG) evaluate electrical transmission, detecting decremental response or increased jitter as proof of signal degradation.
Chest Computed Tomography (CT): Performed to screen for a thymoma (tumor of the thymus gland), present in to of Myasthenia Gravis patients, which acts as a key driver of the autoimmune response.
Glaucoma Diagnostic Tools:
Tonometry: Measures intraocular pressure. Normal baseline intraocular pressure is below . In an acute glaucoma attack, values can shoot past or .
Fundoscopic Examination: Direct visualization of the back of the eye to inspect for optic nerve head cupping (physical structural damage caused by pressure).
Visual Field Testing: Maps out functional loss of peripheral vision.
Gonioscopy: Uses a specialized lens to evaluate whether the iridocorneal drainage angle is physically open or closed.
Pharmacotherapy Strategies
Myasthenia Gravis Pharmacotherapy:
First-Line Treatment: Pyridostigmine, an acetylcholinesterase inhibitor that blocks the enzymatic breakdown of acetylcholine, increasing its availability in the synaptic cleft to bind remaining functional receptors.
Immunomodulation: Corticosteroids or immunosuppressants used to reduce autoantibody production.
Emergent Intervention: Plasmapheresis used during a myasthenic crisis to physically filter and wash attacking autoantibodies out of the patient's blood.
Glaucoma Pharmacotherapy:
Therapeutic Objective: Lower intraocular pressure to prevent optic nerve damage.
First-Line Treatment for Open-Angle Glaucoma: Prostaglandin analogues (e.g., latanoprost), which increase fluid drainage through the secondary uveoscleral outflow pathway.
Aqueous Humor Production Inhibitors: Beta-blockers, which decrease fluid production within the eye.
Miotics: Agents like pilocarpine, which physically contract/stretch the trabecular meshwork to increase fluid outflow.
Clinical Cross-Over and Safety Paradox
Inter-System Pharmacological Hazard:
Beta-blockers are a standard, highly effective treatment used to lower intraocular pressure in glaucoma by suppressing fluid production.
However, beta-blockers impair neuromuscular transmission at the skeletal muscle junction.
Clinical Paradox:
Administering a beta-blocker to treat glaucoma in a patient who also has Myasthenia Gravis can impair neuromuscular transmission so severely that it triggers profound muscle weakness, drooping eyelids, difficulty breathing, or a life-threatening myasthenic respiratory crisis.
If a patient receiving beta-blockers for glaucoma suddenly presents with severe muscle weakness, ptosis, and dyspnea, clinicians must evaluate for unmasked or exacerbated Myasthenia Gravis.